Abstract Details

Title Neurofilament Serum Levels Do Not Correlate with Symptom Burden in Stable, Ocrelizumab-Treated MS Patients Enrolled into SYMptom Burden on Ocrelizumab, a Longitudinal Study (SYMBOLS)

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 336

Objective To examine the correlation between symptom burden, assessed using Neuro-QoL, and serum neurofilament light chain levels in Ocrelizumab-treated MS patients enrolled in the SYMBOLS study.

Background Neurofilament light chain (NfL) is an intraneuronal cytoskeletal component that is released into blood in response to neuronal damage in the central nervous system. NfL is a biomarker of disease prognosis and treatment response in MS. It is not known whether NfL correlates with symptom burden in treated MS patients.

Design/Methods SYMBOLS (NCT04855617) is a prospective, two-center study of symptom fluctuations in OCR-treated MS patients from the NYU MS Care Center (NYU) in New York City and the Elliot Lewis MS Center (ELC) in Massachusetts. Symptom burden, assessed with validated Neuro-QoL instruments, and serum NfL (sNfL) samples are collected two weeks prior to OCR infusion. Spearman's rank-order correlation was used to determine relationships between Neuro-QoL scores and NfL levels; p<0.05 was considered significant.

Results Data was available for 69 out of 106 enrolled patients (mean age 45.1 ± 12.1 years; 63.8% female; 30.4% non-white; 59.4% RRMS, 23.2% SPMS, 17.4% PPMS; mean disease duration 15.9 ± 10.2 years; mean OCR treatment duration 3.4 ± 1.1 years; mean EDSS 3.1 ± 2.1 (EDSS<4, n=46 (66.7%)). No significant correlation was observed between NfL and Neuro-QoL scores in anxiety (p=0.32), depression (p=0.79), fatigue (p=0.09), cognition (p=0.87), dexterity (p=0.71), mobility (p=0.20), sleep disturbance (0.53), social participation (p=0.71), and communication (p=0.07).

Conclusions In stable, OCR-treated MS patients, NfL does not correlate with symptom burden as assessed with Neuro-QoL. Additional analyses, with adjustment for age, EDSS, disease subtype, and OCR treatment duration will be presented.

Authors/Disclosures
Ilya Kister, MD, FAAN (NYU School of Medicine) PRESENTER	Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Andrew J. Bouley, MD (The Elliot Lewis Center)	Dr. Bouley has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Bouley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Bouley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Bouley has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Bouley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Bouley has received research support from Novartis.
Ellen S. Lathi, MD	No disclosure on file
Joshua D. Katz, MD (The Elliot Lewis Center)	The institution of Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Theraputics. The institution of Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen Pharmaceuticals. The institution of Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. The institution of Dr. Katz has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Katz has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Sanofi-Genzyme. The institution of Dr. Katz has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Genentech. The institution of Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD-Serono.

��ɫ��

��ɫ��